sim0686
Locally Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Locally Advanced Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
[131]i-iaza University of Alberta | Phase 1/2 | CC |
ANTI-GLOBO H MONOCLONAL ANTIBODY OBI-888 OBI Pharma, Inc | Phase 1/2 | CC |
Repotrectinib Turning Point Therapeutics, Inc. | Phase 1/2 | CC |
Vcn-01 Theriva Biologics SL | Phase 1 | CC |
Retifanlimab Incyte Corporation | Phase 1 | CC |
View all 9 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →